Our studies clearly show that tracer Me4FDG is accumulated in pancreatic and prostate tumors in vitro and high-grade glioblastomas in vivo, and this is correlated with the immunochemical detection of SGLT2. This evidence concerns the gene SLC5A2 and glioblastoma.